Related Experiment Video
Updated: Jun 29, 2025
11:27
Analysis of SCAP N-glycosylation and Trafficking in Human Cells
Published on: November 8, 2016
8.7K
The roles and mechanisms of SREBP1 in cancer development and drug response
Ying He1,2, Shasha Qi1,2, Lu Chen1,2
1School of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China.
Genes & Diseases
|April 1, 2024
Summary
Sterol regulatory element-binding transcription factor 1 (SREBP1) drives cancer by altering lipid and glucose metabolism. Targeting SREBP1 pathways offers potential for novel cancer therapies and improved treatment responses.
Area of Science:
- Molecular Biology
- Cancer Biology
- Metabolic Diseases
Background:
- Cancer progression is linked to altered lipid and glucose metabolism.
- Sterol regulatory element-binding transcription factor 1 (SREBP1) is a key regulator of lipid synthesis and homeostasis.
- SREBP1 and its targets are implicated in various metabolic diseases, including cancer.
Purpose of the Study:
- To review the multifaceted roles and mechanisms of SREBP1 in cancer biology.
- To explore SREBP1's involvement in metabolic reprogramming, immunity, and tumor microenvironment.
- To discuss SREBP1's potential in cancer prognosis, drug response, and therapeutic targeting.
Main Methods:
- Comprehensive literature review and synthesis of existing research on SREBP1 in cancer.
- Analysis of SREBP1's regulatory functions in cellular processes relevant to cancer.
- Discussion of clinical implications, including prognostic value and therapeutic strategies.
Main Results:
- SREBP1 significantly influences cancer cell proliferation, invasion, and metastasis through metabolic reprogramming.
- SREBP1 impacts key cancer hallmarks including cell cycle, apoptosis, ferroptosis, and epithelial-mesenchymal transition.
- SREBP1 plays a role in modulating the tumor microenvironment and immune response within tumors.
Conclusions:
- SREBP1 is a critical mediator of metabolic alterations in cancer, impacting multiple oncogenic pathways.
- Understanding SREBP1's functions provides insights into cancer progression and resistance mechanisms.
- Targeting SREBP1 and its pathways presents a promising avenue for developing novel cancer therapeutics and improving patient outcomes.
More Related Videos
07:34Quantitative Determination of De Novo Fatty Acid Synthesis in Brown Adipose Tissue Using Deuterium Oxide
Published on: May 12, 2023
1.0K
10:51Reverse Yeast Two-hybrid System to Identify Mammalian Nuclear Receptor Residues that Interact with Ligands and/or Antagonists
Published on: November 15, 2013
12.8K
Related Concept Videos
01:45Regulation of Nuclear Protein Sorting
2.4K
Nuclear protein sorting regulates nucleus composition and gene expression, crucial for determining the fate of a eukaryotic cell. Hence, the entry and exit of molecules across the nuclear envelope is a tightly controlled process. Nuclear protein sorting can be inhibited by one of the following ways: 1) masking cargo signal sequences, 2) modifying the nuclear receptor's affinity for cargo, 3) controlling the nuclear pore size, 4) retaining the cargo during its transit to the cytosol or the...
2.4K
01:31Transducer Mechanism: Nuclear Receptors
1.3K
Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
1.3K
03:03mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.5K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.5K
01:28Structure-Activity Relationships and Drug Design
716
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
716
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K